Abstract:Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease with dire consequences and in urgent need of improved therapies. Compelling evidence indicates that damage or dysfunction of AT2s is of central importance in the development of IPF. We recently identified a novel AT2 subpopulation characterized by low SFTPC expression but that is enriched for PD-L1 in mice. These cells represent quiescent, immature AT2 cells during normal homeostasis and expand upon pneumonectomy (PNX) and were consequently named injury-activated alveolar progenitors (IAAPs). FGF10 is shown to play critical roles in lung development, homeostasis, and injury repair demonstrated in genetically engineered mice. In an effort to bridge the gap between the promising properties of endogenous Fgf10 manipulation and therapeutic reality, we here investigated whether the administration of exogenous recombinant FGF10 protein (rFGF10) can provide preventive and/or therapeutic benefit in a mouse model of bleomycin-induced pulmonary fibrosis with a focus on its impact on IAAP dynamics. C57BL/6 mice and SftpcCreERT2/+; tdTomatoflox/+ mice aged 8–10 weeks old were used in this study. To induce the bleomycin (BLM) model, mice were intratracheally (i.t.) instilled with BLM (2 μg/g body weight). BLM injury was induced after a 7-day washout period following tamoxifen induction. A single i.t. injection of rFGF10 (0.05 μg/g body weight) was given on days 0, 7, 14, and 21 after BLM injury. Then, the effects of rFGF10 on BLM-induced fibrosis in lung tissues were assessed by H&E, IHC, Masson's trichrome staining, hydroxyproline and Western blot assays. Immunofluorescence staining and flow cytometry was used to assess the dynamic behavior of AT2 lineage-labeled SftpcPos (IAAPs and mature AT2) during the course of pulmonary fibrosis. We observed that, depending on the timing of administration, rFGF10 exhibited robust preventive or therapeutic efficacy toward BLM-induced fibrosis based on the evaluation of various pathological parameters. Flow cytometric analysis revealed a dynamic expansion of IAAPs for up to 4 weeks following BLM injury while the number of mature AT2s was drastically reduced. Significantly, rFGF10 administration increased both the peak ratio and the duration of IAAPs expansion relative to EpCAMPos cells. Altogether, our results suggest that the administration of rFGF10 exhibits therapeutic potential for IPF most likely by promoting IAAP proliferation and alveolar repair.

The Establishment of Lung Slice Fibrosis Induced by Transforming Growth Factor-Β_1

Bioengineered in Vitro Tissue Model of Fibroblast Activation for Modeling Pulmonary Fibrosis

Evaluation of an ex vivo fibrogenesis model using human lung slices prepared from small tissues

Expression of Tgf-Beta(1), Pdgf and Igf-1 Mrna in Lung of Bleomycin-A(5)-Induced Pulmonary Fibrosis in Rats

Therapeutic Targeting of Src Kinase and Myofibroblast Activation in Pulmonary Fibrosis

Mice Overexpressing Latent Tgf-Beta 1 Are Protected Against Renal Fibrosis In Obstructive Kidney Disease

Release of biologically active TGF-β1 by alveolar epithelial cells results in pulmonary fibrosis

Tuberostemonine may alleviates proliferation of lung fibroblasts caused by pulmonary fibrosis

The Effect of Huqihuoxue Decoct on TGF-β_1 and Pathological Change in Pulmonary Fibrosis Rats Model

TGF{beta} drives fibrotic remodeling via modulation of homeostatic and pathological fibroblast populations in a murine model of pulmonary fibrosis

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

Regulatory Mechanisms of TGF‐β1‐induced Fibrogenesis of Human Alveolar Epithelial Cells

Latent transforming growth factor-β1 protects against bleomycin-induced lung injury in mice.

Transforming growth factor-β1 promotes mechanical ventilation-associated pulmonary fibrosis through mediating aerobic glycolysis

Effect of high glucose supplementation on pulmonary fibrosis involving reactive oxygen species and TGF-β

Effect of Serum TGF-β Level on Hepatic Fibrosis of Rats

Expression Change of TGF Β1 in Lungs of Rats′ Bleomycin-indued Pulminany Gibrosis Model

FGF10 Therapeutic Administration Promotes Mobilization of Injury-Activated Alveolar Progenitors in a Mouse Fibrosis Model

TGF-β, Smad3 and the process of progressive fibrosis

Transforming Growth Factor-β1 Stimulates the Proliferation of Rat Lung Fibroblasts in vitro

Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities